A combination of valproic acid sodium salt, CHIR99021, E-616452, tranylcypromine, and 3-Deazaneplanocin A causes stem cell-like characteristics in cancer cells

Sha, Shuang; Zhai, Yuanfen; Lin, Chengzhao; Wang, Heyong; Chang, Qing; Song, Shuang; Ren, Mingqiang; Liu, Gentao

doi:10.18632/oncotarget.18396

Cited by 3 publications

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The low availability of stem cells could be a limitation for their use in cell therapy. Sha et al [ 24 ] stimulated A549 lung cancer cells to display stem-cell-like characteristics (including nestin expression) using a combination of five small molecules. This strategy could provide a potential therapeutic approach for use in the treatment of lung diseases, including cancer.…”

Section: Nestin-expressing Cells In the Adult Lungmentioning

confidence: 99%

Nestin-Expressing Cells in the Lung: The Bad and the Good Parts

Jaramillo‐Rangel

Chávez-Briones

Ancer-Arellano

et al. 2021

Cells

View full text Add to dashboard Cite

Nestin is a member of the intermediate filament family, which is expressed in a variety of stem or progenitor cells as well as in several types of malignancies. Nestin might be involved in tissue homeostasis or repair, but its expression has also been associated with processes that lead to a poor prognosis in various types of cancer. In this article, we review the literature related to the effect of nestin expression in the lung. According to most of the reports in the literature, nestin expression in lung cancer leads to an aggressive phenotype and resistance to chemotherapy as well as radiation treatments due to the upregulation of phenomena such as cell proliferation, angiogenesis, and metastasis. Furthermore, nestin may be involved in the pathogenesis of some non-cancer-related lung diseases. On the other hand, evidence also indicates that nestin-positive cells may have a role in lung homeostasis and be capable of generating various types of lung tissues. More research is necessary to establish the true value of nestin expression as a prognostic factor and therapeutic target in lung cancer in addition to its usefulness in therapeutic approaches for pulmonary diseases.

show abstract

Section: Nestin-expressing Cells In the Adult Lungmentioning

confidence: 99%

Nestin-Expressing Cells in the Lung: The Bad and the Good Parts

Jaramillo‐Rangel

Chávez-Briones

Ancer-Arellano

et al. 2021

Cells

View full text Add to dashboard Cite

show abstract

Notch signaling and targeted therapy in non-small cell lung cancer

Sun,

Dong,

Xiang

et al. 2024

Cancer Letters

View full text Add to dashboard Cite

Novel drug candidates for treating esophageal carcinoma: A study on differentially expressed genes, using connectivity mapping and molecular docking

et al. 2018

View full text Add to dashboard Cite

Patients with esophageal carcinoma (ESCA) have a poor prognosis and high mortality rate. Although standard therapies have had effect, there is an urgent requirement to develop novel options, as increasing drug tolerance has been identified in clinical practice. In the present study, differentially expressed genes (DEGs) of ESCA were identified in The Cancer Genome Atlas and Genotype-Tissue Expression databases. Functional and protein-protein interaction (PPI) analyses were performed. The Connectivity Map (CMAP) was selected to predict drugs for the treatment of ESCA, and their target genes were acquired from the Search Tool for Interactions of Chemicals (STITCH) by uploading the Simplified Molecular-Input Line-Entry System structure. Additionally, significant target genes and ESCA-associated hub genes were extracted using another PPI analysis, and the corresponding drugs were added to construct a network. Furthermore, the binding affinity between predicted drug candidates and ESCA-associated hub genes was calculated using molecular docking. Finally, 827 DEGs (|log2 fold-change|≥2; q-value <0.05), which are principally involved in protein digestion and absorption (P<0.005), the plasminogen-activating cascade (P<0.01), as well as the ‘biological regulation’ of the Biological Process, ‘membrane’ of the Cellular Component and ‘protein binding’ of the Molecular Function categories, were obtained. Additionally, 11 hub genes were obtained from the PPI network (all degrees ≥30). Furthermore, the 15 first screen drugs were extracted from CMAP (score <−0.85) and the 9 second screen drugs with 70 target genes were extracted from STITCH. Furthermore, another PPI analysis extracted 51 genes, and apigenin, baclofen, Prestwick-685, menadione, butyl hydroxybenzoate, gliclazide and valproate were selected as drug candidates for ESCA. Those molecular docking results with a docking score of >5.52 indicated the significance of apigenin, Prestwick-685 and menadione. The results of the present study may lead to novel drug candidates for ESCA, among which Prestwick-685 and menadione were identified to be significant new drug candidates.

show abstract

A combination of valproic acid sodium salt, CHIR99021, E-616452, tranylcypromine, and 3-Deazaneplanocin A causes stem cell-like characteristics in cancer cells

Cited by 3 publications

References 40 publications

Nestin-Expressing Cells in the Lung: The Bad and the Good Parts

Nestin-Expressing Cells in the Lung: The Bad and the Good Parts

Notch signaling and targeted therapy in non-small cell lung cancer

Novel drug candidates for treating esophageal carcinoma: A study on differentially expressed genes, using connectivity mapping and molecular docking

Contact Info

Product

Resources

About